AcquisitionsMay 13, 2026, 03:51 PM
Stereotaxis to Acquire Robocath; Q1 Revenue Down to $6.29M
AI Summary
Stereotaxis, Inc. announced an agreement to acquire Robocath, a French innovator in advanced mechanical robotic technology for interventional cardiology and neurointerventions, on April 14, 2026. For the first quarter ended March 31, 2026, the company reported a decrease in total revenue to $6.29 million from $7.47 million in the prior year period. Net loss attributable to common stockholders increased slightly to $6.17 million, or $0.06 per share, compared to $6.14 million, or $0.07 per share, in Q1 2025. The company also secured $4.72 million in financing activities, primarily from an at-the-market equity offering.
Key Highlights
- Stereotaxis entered an agreement to acquire Robocath on April 14, 2026.
- Total revenue for Q1 2026 decreased to $6.29 million from $7.47 million in Q1 2025.
- Net loss attributable to common stockholders was $6.17 million ($0.06 per share) in Q1 2026.
- Systems revenue decreased to $1.32 million in Q1 2026 from $1.96 million in Q1 2025.
- Disposables, service, and accessories revenue was $4.97 million in Q1 2026, down from $5.51 million.
- Net cash provided by financing activities was $4.72 million in Q1 2026, including $4.58 million from equity issuance.
- Cash and cash equivalents increased to $14.62 million as of March 31, 2026.
- MAGiC catheter received FDA 510(k) clearance in January 2026, replacing J&J catheters.
Price Impact
More from STXS